Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Polycystic Kidney Disease Drugs Market Size

The polycystic kidney disease drugs market was valued at USD 0.51 billion in 2023, driven by rising incidence of autosomal dominant polycystic kidney disease across the 8 major markets. The market is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, with the values likely to reach USD 0.86 billion by 2032.

Polycystic Kidney Disease Drugs Market Outlook

  • The market growth is fueled by increasing collaborative efforts between pharmaceutical firms and research institutions to spur advanced therapies targeting polycystic kidney disease (PKD) mechanisms.
  • Increasing incidence of drugs FDA approvals for treating polycystic kidney disease is amongst the major market trends.
  • Technological innovations in drug development, like high-throughput screenings and personalized medicine are expected to fuel the demand for polycystic kidney disease drugs in the forecast period.

Global Polycystic Kidney Disease Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Polycystic Kidney Disease Drugs Market Overview

Polycystic kidney disease (PKD) drugs are designed to address the formation of fluid-filled cysts in kidneys, which can lead to kidney dysfunction. The rising prevalence of PKD and the urgent need for effective treatments are driving market growth. The application of advanced technologies such as artificial intelligence and machine learning to generate high efficacy drugs is expected to impact the market landscape significantly. In addition, continued research initiatives, focused on significantly enhancing the scope and growth of the PKD drugs is amongst the major market trends.

Polycystic Kidney Disease Drugs Market Growth Drivers

Increasing Prevalence of Polycystic Kidney Disease (PKD) to Affect the Market Landscape Significantly

Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease, affecting 1 in 500 to 1,000 individuals globally. It is especially exacerbated by diabetes and hypertension. Consequently, rising prevalence of diabetes and obesity, which can be attributed to sedentary lifestyle and lack of an exercise regime can lead to heightened demand for polycystic kidney disease drugs in the coming years.

Surge in FDA Approvals to Meet Rising Polycystic Kidney Disease Drugs Market Demand

In September 2023, the United States FDA approved Eli Lilly’s Jardiance® (empagliflozin) 10 mg tablets for the treatment of chronic kidney disease (CKD). This approval introduced a promising treatment option for over 35 million affected adults, marking a substantial milestone in CKD management. Empagliflozin demonstrated efficacy in slowing CKD progression, as evidenced in the EMPA-KIDNEY phase III trial, and included a notable reduction in hospitalization risks as well.

Polycystic Kidney Disease Drugs Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Key Trends Impact
Adoption of Innovative Methodologies to Develop Effective Drugs  The persistent lack of targeted therapies to halt cyst growth and preserve kidney function underscores the urgent need for innovation drug development in PKD, potentially reshaping treatment approaches.
Suge in Research Efforts  Expanding research endeavors into PKD pathophysiology hold the potential to revolutionize treatment paradigms by unravelling novel therapeutic targets and paving the way for precision medicine tailored to individual patient profile.
Advancements in Technology  Technological innovations like high-output screening and computational modeling expedite the identification and optimization of potential PKD drug candidates. Such advancements usher in next-generation treatments with enhanced efficacy and safety profiles. Drug repurposing intended to recognize new clinical indications for approved or investigational medications is being employed in drug development, attributed to its cost efficiency and time saving benefits.
Increasing Preference for Personalized medicines  The increasing adoption of personalized medicine approaches, leveraging genomics and biomarker to reshape PKD drugs is a significant market trend. It can enable tailored therapeutic interventions based on individual patient characteristics, ultimately enhancing patient care and quality of life.

Global Polycystic Kidney Disease Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Polycystic Kidney Disease Drugs Market Segmentation

Market Breakup by Disease Type

  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Polycystic Kidney Disease Drugs Market Share

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Leads the Market Share Based on Type

The market segmentation based on disease type is divided into autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). Out of these, ADPKD emerges as the predominant leader in the polycystic kidney disease drugs market. Its high prevalence among PKD cases secures a significant market share, surpassing its rare counterpart, autosomal recessive polycystic kidney disease (ARPKD).

Global Polycystic Kidney Disease Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Polycystic Kidney Disease Drugs Market Analysis by Region

The market for polycystic kidney disease drugs spans across United States, EU-4 (Germany, France, Italy and Spain), the United Kingdom, Japan and India, with each region significantly contributing to its dynamics. United States stands out as a market leader. Its market value due can be accredited to higher prevalence of PKD in the region. Having a robust regulatory infrastructure also adds notable value. In March 2024, Vertex Pharmaceuticals (VRTX ) received U.S. Food and Drug Administration (FDA) approval for VX- 407, an investigational drug targeting ADPKD. VX-407 is a small molecular corrector, which addresses the underlying cause of ADPKD in patients with specific PKD1 genetic variants.

ADPKD is the most common inherited kidney disease that affects an estimated 250,000 individuals in the United States and Europe combined. Consequently, Europe also holds a significant market share for polycystic kidney disease drugs. In Europe, the presence of affluent research institutions along with a well-established research infrastructure play a critical role in boosting the market value.

Leading Players in the Polycystic Kidney Disease Drugs Market

They key features of the market report include patent analyses, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd, headquartered in Basel, Switzerland, was founded in 1896. The company specializes in pharmaceutical manufacturing and is a leader in the field of cancer drug development and sales. Roche has developed drugs and diagnostics for various disease, including PKD-1 inhibitors. Some of the drugs include Mycophenolate Mofetil (Cellcept), and Valganciclovir (Valcyte).

Galapagos NV

Galapagos NV, founded in 1999 as a joint venture between Crucell and Tibotec, is headquartered in Mechelen, Belgium. The company specializes in pharmaceutical research and is developing GLPG2737, a CFTR1 inhibitor to treat polycystic kidney disease (ADPKD).

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. was established in 1886 in New Brunswick. The company is developing JNJ-0237, an oral medication to treat ADPKD.

Merck and Co. Inc.

Merck and Co. Inc. was founded in 1891, in New York. The company is amongst the leading companies in pharmaceutical development and boasts an elaborate drugs portfolio for a variety of diseases including polycystic kidney disease.

Other companies in the market include AbbVie Inc., Apotex Inc., Amgen Inc., Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Regulus Therapeutics, Sanofi SA, XORTX Therapeutics Inc., Novartis AG, Teva Pharmaceutical Industries Ltd, and Bayer AG

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Disease Type
  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Apotex Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Johnson & Johnson Services, Inc.
  • Merck and Co. Inc.
  • Otsuka Holdings Co. Ltd
  • Palladio Biosciences Inc.
  • Regulus Therapeutics 
  • Sanofi SA
  • XORTX Therapeutics Inc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

Key Questions Answered in the Polycystic Kidney Disease Drugs Market Report

  • What was the polycystic kidney disease drugs market value in 2023?
  • What is the polycystic kidney disease drugs market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What are the major factors aiding the polycystic kidney disease drugs market demand? 
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • What are the major polycystic kidney disease drugs market trends?
  • What is the market segmentation based on route of administration?
  • What is the market breakup based on disease types?
  • What is the market segmentation based on distribution channels?
  • How does the rise in the geriatric population impact the market size?
  • Who are the key players involved in the polycystic kidney disease drugs market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
  • What is the clinical trials landscape of the market?
  • What is the patent scenario of the market?
  • Which factors contribute to the dominance of ADPKD drugs in the market?

Polycystic Kidney Disease Drugs Market Report Snapshots

Polycystic Kidney Disease Drugs Market Size

Polycystic Kidney Disease Drugs Market Growth

Polycystic Kidney Disease Drugs Market Trends

Polycystic Kidney Disease Drugs Market Share

Polycystic Kidney Disease Drugs Market Regional Analysis

Polycystic Kidney Disease Drugs Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124